A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-08-14) →
What happened
Solum updated the disclosed terms of a subsidiary's acquisition of Icure Pharmaceutical Incorporation, now worth US$14.9M.
For context, this deal is worth about 1.7% of the company's consolidated total assets.
| Target | Icure Pharmaceutical Incorporation |
|---|---|
| Deal value | US$14.9M |
| vs. company assets | 1.7% |
| Filed | 2026-08-05, [Amended] Decision to acquire shares/equity in another company (voluntary) (subsidiary) |
| Source | DART rcept 20260805800623 → open original filing |
Versions of this filing
- 2026-06-29Original
- 2026-08-05Amendment 1 (this page)
- 2026-08-13Amendment 2
- 2026-08-14Amendment 3
Source: DART. Information only, not investment advice.